Sanofi - Aventis Groupe: Press release: Late-breaking Phase

Late-breaking Phase 3 data at AAD 2022 show Dupixent (dupilumab) significantly improved signs and symptoms of prurigo nodularis Dupixent significantly reduced itch at 12 weeks, and at 24 weeks nearly

Related Keywords

Japan , United States , Paris , France General , France , American , Eva Schaefer Jansen , Corentine Driancourt , Gil Yosipovitch , Felix Lauscher , Vesna Tosic , Hannah Kwagh , Nathalie Pham , Sally Bain , Priya Nanduri , Regeneron Pharmaceuticals Inc , Twitter , Regeneron Genetics Center , Dupilumab Development Program , Nasdaq , Teva Pharmaceutical Industries Ltd , Exchange Commission , American Academy Of Dermatology , University Of Miami , Miller School Of Medicine , Euronext , Late Breaking Phase , American Academy , Miller School , Worst Itch Numeric Rating Scale , Global Assessment , Private Securities Litigation Reform Act , Statement Regarding Forward Looking , Forward Looking Statements , Regeneron Pharmaceuticals , Product Candidates , Teva Pharmaceutical Industries , Sanofi , Eventis , Roupe , Dress , Release , Gate , Breaking , Hase , Data , 022 , Show , Dupixent , Dupilumab , Ignificantly , Mproved , Signs , Symptoms , Prurigo , Nodularis ,